Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

BackgroundDiffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor–neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure, si...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Vivian Lee, Qishi Zheng, Desiree-Faye Toh, Chee Jian Pua, Jennifer A. Bryant, Chi-Hang Lee, Stuart A. Cook, Javed Butler, Javier Díez, A. Mark Richards, Thu-Thao Le, Calvin W. L. Chin
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2023-08-01
Reeks:	Frontiers in Cardiovascular Medicine
Onderwerpen:	myocardial fibrosis sacubitril/valsartan ARNi hypertensive heart disease heart failure cardiovascular magnetic resonance imaging
Online toegang:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1248468/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!